News BioPulse – New cancer center breaks ground The State of Maryland's Pulse on the Bio Industry. (more…)Super UserMay 22, 2012
News Who’s on Biotech’s Endangered Species List? Mid-Sized Drug Developers | Xconomy Only a few companies have ever been successful enough to call themselves Big Biotechs. If boards and shareholders lack vision and…Super UserMay 21, 2012
News Cleveland Clinic to help Notre Dame commercialize medical innovations Following on the heels of two hospitals, the University of Notre Dame has become the first university to strike a…Super UserMay 21, 2012
News Osiris becomes first company to market stem-cell therapy – Baltimore Business Journal Osiris Therapeutics Inc. in Columbia has become the world’s first company to receive market approval for a manufactured stem cell…Super UserMay 18, 2012
News Emergent gets FDA approval for modified vaccine dosing – Washington Business Journal Rockville-based Emergent BioSolutions Inc. , which makes the only vaccine licensed by the Food and Drug Administration to protect against…Super UserMay 18, 2012
News United Therapeutics to Own Even More of Downtown Silver Spring United Therapeutics, which has has greatly expanded their downtown Silver Spring presence as of late, is reportedly set to purchase…Super UserMay 18, 2012
News Human Genome Sciences adopts stockholder rights plan – Baltimore Business Journal Human Genome Sciences Inc, which has rejected a hostile $13-per-share offer from GlaxoSmithKline, has adopted a short-term stockholder rights plan…Super UserMay 17, 2012
News Two INNoVATE Students Take First Place in Maryland Business Plan Competition ‹ Hopkins Happenings When Adam Steele worked at the National Institute of Standards and Technology (NIST), he and two other colleagues invented a…Super UserMay 17, 2012
News The top 5 complications of FDA medical device trials “You do a really good job with complex trials.” We’re lucky to say that we’ve heard this from several clients…Super UserMay 17, 2012
News Human Genome Sciences Board of Directors Unanimously Determines GlaxoSmithKline Unsolicited Tender Offer is Inadequate and Not in the Best Interests of Stockholders – MarketWatch Human Genome Sciences, Inc.oday announced that its Board of Directors, after careful review and consideration with the assistance of the…Super UserMay 17, 2012